Affiliation:
1. Republican Scientific and Practical Center for Pediatric Oncology, Hematology and Immunology, Ministry of Health of the Republic of Belarus
Abstract
Chronic myeloid leukemia (CML) in children is rare, less than 3 % of all cases of leukemia in pediatric practice. Along with the successes achieved in the treatment of CML with imatinib, it’s necessary to study of molecular factors in predicting resistance to therapy. According to the literature, about 30 % of adult patients with imatinib resistance have point mutations in the kinase domain of BCR-ABL1 gene. The number of reports about mutation spectrum of the BCR-ABL1 gene in children with resistant forms of CML is limited. This article describes the clinical case of secondary resistance to imatinib in a 15-year-old girl with the F359C mutation of BCR-ABL1 gene and a review of the literature.
Subject
Oncology,Hematology,Pediatrics, Perinatology, and Child Health
Reference26 articles.
1. Wang X., Zheng B., Li S., Mulvihill J. J., Chen X., Liu H. Automated identification of abnormal metaphase chromosome cells for the detection of chronic myeloid leukemia using microscopic images. J Biomed Opt 2010;15(4):046026. doi: 10.1117/1.3476336.
2. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000;96(10):3343–56. PMID: 11071626.
3. Suttorp S., Schulze Ph., Glauche I., Gohring G., von Neuhoff N., Metzler M., Sedlacek P., de Bont E., Balduzzi A., Lausen B., Aleinikova O., Sufliarska S., Henze G., Strauss G., Eggert A., Kremens B., Groll A.H., Berthold F., Klein C., Groß-Wieltsch U., Sykora K.W., Borkhardt A., Kulozik A.E., Schrappe M., Nowasz C., Krumbholz M., Tauer J.T., Claviez A., Harbott J., Kreipe H.H., Schlegelberger B., Thiede C. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 2018;32(7):1657–69. doi: 10.1038/s41375-018-0179-9.
4. Baccarani M., Pileri S., Steegmann J., Muller M., Soverini S., Dreyling M.; ESMO Guidelines Working Group. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii72–7. doi:10.1093/annonc/mds228.
5. Kutsev S.I., Vel'chenko M.V. Znachenie analiza mutatsii gena BCR--ABL v optimizatsii targetnoi terapii khronicheskogo mielo-leikoza. Klinicheskaya onkogematologiya 2008;1(3):190-9. ID: 11670881. [Kutsev S.I., Velchenko M.V. The role of BCR-ABL gene mutation analysis in the optimization of target therapy of chronic myeloid leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2008;1(3):190–9 (In Russ.)].